Objectives Antiphospholipid syndrome (APS) is associated with neurological manifestations
and one of the novel autoantigens associated with this disease is Annexin A2 (ANXA2). In …

Antiphospholipid syndrome (APS) affects coagulation and the brain by autoimmune
mechanisms. The major antigen in APS is beta-2-glycoprotein I (β2-GPI) is known to …

Background Autoimmune diseases, like multiple sclerosis, are triggered by uncontrolled
activation of cells of the immune system against self-antigen present, for instance, in the …

Annexin A1 (ANXA1) is an endogenous protein known to have potent anti-inflammatory
properties in the peripheral system. It has also been detected in the brain, but its function …

Annexin A2 (ANXA2, an endothelial cell receptor for plasminogen and tissue plasminogen
activator) has been identified as a new autoantigen in antiphospholipid syndrome (APS) …

Patients suffering from autoimmune diseases are more susceptible to mental disorders yet,
the existence of specific cellular and molecular mechanisms behind the co-morbidity of …

Background The toxicity of amyloid-β (Aβ) peptide present in the brain of Alzheimer's
disease (AD) patients is thought to be mediated via the increased secretion of pro …

Antiphospholipid syndrome (APS) has been defined as a clinical and laboratory entity.
Laboratory criteria include the presence of anticardiolipin antibodies (aCL) and/or lupus …

Abstract Annexin-A1 (Anx-A1) is an endogenous anti-inflammatory molecule and while
described as a repressor of innate immune responses, the role of Anx-A1 in adaptive …

A hallmark feature of antiphospholipid syndrome (APS) is the presence of antiphospholipid
antibodies (aPLs). Few studies have addressed the clinical relevance of anti-annexin A5 …